[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatogenic-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatogenic-diabetes-mellitus":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644103","prediction-of-pancreatogenic-diabetes-after-partial-resection-of-the-pancreas-100644103",false,"NCT07665710","Prediction of Pancreatogenic Diabetes After Partial Resection of the Pancreas","Inclusion Criteria:\n\n* age ≥ 18 years\n* planned partial resection of the pancreas\n* absence of known diabetes before the procedure\n* absence of known borderline basal glycemia before the procedure\n* absence of impaired glucose tolerance before the procedure\n* signed written informed consent\n\nExclusion Criteria:\n\n* known diabetes mellitus before the procedure\n* known borderline basal glycemia before the procedure\n* impaired glucose tolerance before the procedure\n* inability to provide informed consent\n* withdrawal of consent during the course of the study\n* incomplete key data\n* total resection of the pancreas\n* a subsequent decision for conservative treatment (based on clinical characteristics at the time of the surgical procedure)","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","OBSERVATIONAL","The primary aim of the study is to identify clinical, laboratory, imaging, and pathohistological risk factors for the development of pancreatogenic diabetes after partial resection of the pancreas (PRP) and, based on these, to build a predictive model that would enable reliable and accurate identification of patients who will develop pancreatogenic diabetes. A review of the literature shows that there is currently no validated tool available in clinical practice for identifying patients at risk of this type of diabetes after PRP. Etiological differences between type 2 diabetes and pancreatogenic diabetes often lead to late diagnosis, limiting opportunities for timely intervention. The development of a comprehensive predictive model would contribute to a better understanding of the pathophysiology of pancreatogenic diabetes, enable the identification of patients at risk, facilitate tailored clinical monitoring, and allow the implementation of targeted preventive or therapeutic measures in the perioperative period.\n\nBased on a review of the literature and clinical observations, the investigators formulated the following hypotheses:\n\nH1: Clinical, laboratory, imaging, and pathohistological variables are independently associated with the development of pancreatogenic diabetes after partial pancreatic resection.\n\nH2: A predictive model that allows reliable and accurate identification of patients who will develop pancreatogenic diabetes can be build based on the identified variables (H1).\n\nH3: A comprehensive predictive model in the perioperative period allows more precise identification of patients who will develop pancreatogenic diabetes, and thus more effective risk stratification compared to the use of individual risk factors (variables).\n\nBased on the reviewed literature and our own clinical observations, this constitutes an original contribution to science. The investigators expect that the research will identify key clinical, laboratory, imaging, and pathohistological factors associated with the development of pancreatogenic diabetes after partial pancreatic resection. The development of a clinically useful predictive model that will allow individual risk assessment for the development of pancreatogenic diabetes in patients after partial pancreatic resection is anticipated. A similar comprehensive model has not yet been described in the accessible literature. The research will contribute to a better understanding of metabolic changes and will enable the identification of patients who will develop pancreatogenic diabetes after partial pancreatic resection. The results of the study could provide a basis for improved perioperative monitoring of these patients in the field of pancreatogenic diabetes.",[23],"Pancreatogenic Diabetes Mellitus",[25,26,27,28,29,30],"Partial Pancreatectomy","Pancreatogenic Diabetes","Prediction Model","Pancreas Volume","C-peptide","HOMA-IR","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-24","ACTUAL",{"date":37,"type":35},"2026-04-01",{"date":39,"type":19},"2029-04-01",{"name":41,"class":42},"University Medical Centre Ljubljana","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100632380","assessment-of-pancreatic-dysfunction-in-patients-with-type-2-diabetes-100632380","NCT07512934","Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes","Integrated Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes: a Cross-sectional Study Protocol","T3cDM-AKT","Inclusion Criteria:\n\n* • adult patients of Kazakh nationality aged 18 to 74 years\n* diagnosis of T2DM established according to ADA criteria and documented in medical records\n* disease duration ≤5 years\n* absence of ketoacidosis episodes within the last 6 months\n\nExclusion Criteria:\n\n* positive anti-glutamic acid decarboxylase antibodies (anti-GAD65);\n* acute or chronic infections affecting metabolic status within the previous 4 weeks;\n* any history of malignant neoplasms;\n* pregnancy or lactation;\n* previously diagnosed type 1 diabetes mellitus or other specific types of diabetes;\n* severe decompensated chronic diseases;\n* conditions associated with systemic fibrosis (e.g., liver cirrhosis or autoimmune diseases);\n* refusal to participate.","74 Years",{"count":54,"type":19},310,"The goal of this observational study is to better understand how the pancreas works in adults with type 2 diabetes. The study focuses on both hormone production (endocrine function) and digestive function (exocrine function) of the pancreas.\n\nThe main questions it aims to answer are:\n\n* Can problems with the pancreas help identify a different type of diabetes called pancreatogenic diabetes?\n* How are blood markers and pancreas structure related to pancreatic function?\n\nParticipants will:\n\n* Have blood tests to measure glucose, insulin, and other markers\n* Provide a stool sample to assess digestive function\n* Undergo an ultrasound examination of the pancreas\n* Answer questions about digestive symptoms\n\nThe study will take place during a single visit in outpatient clinics.",[23,57,58],"Type 2 Diabetes Mellitus (T2DM)","Exocrine Pancreatic Insufficiency (EPI)",[60,61,62,63,64,65,66,67,68],"Type 3c diabetes","Pancreatogenic diabetes","Fecal elastase-1","TGF-beta1","Adiponectin","IL-1 receptor antagonist","Pancreatic ultrasound","PEI-Q","Type 2 Diabetes Mellitus","2026-04-02",{"date":71,"type":35},"2026-04-06",{"date":73,"type":35},"2025-07-07",{"date":75,"type":19},"2026-12-01",{"name":77,"class":42},"West Kazakhstan Marat Ospanov Medical University"]